A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Trial Profile

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs LN 145 (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 11 Oct 2017 According to an Iovance Biotherapeutics media release, results from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
    • 16 Aug 2017 According to an Iovance Biotherapeutics media release, the first patient has been dosed in this trial. Initial data from this trial are expected in 2018.
    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top